“…Subsequently, several large-scale high-throughput sequencing studies have uncovered that de novo, likely genedisrupting mutations in FOXP1 are among the most significantly recurrent mutations in ASD or ID/NDD cohorts (Coe et al, 2019;Coe et al, 2014;Iossifov et al, 2014;Stessman et al, 2017). To date, over 40 pathogenic variants have been documented, and distinctive neurodevelopmental phenotypes associated with FOXP1 mutations have emerged from the many published case reports (Le Fevre et al, 2013;Mutlu-Albayrak & Karaer, 2019;Palumbo et al, 2013;Sollis et al, 2016;Song, Makino, Noguchi, & Arinami, 2015;Thevenon et al, 2014;Urreizti et al, 2018;Vuillaume et al, 2018;Yamamoto-Shimojima, Okamoto, Matsumura, Okazaki, & Yamamoto, 2019). As with FOXP2 mutations, it is again important to note that these FOXP1 mutations may result in haploinsufficiency or dominant negative effects of mutant proteins, and further functional work is needed to disentangle the molecular mechanisms leading to patient phenotypes.…”